ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

(2015) Thomas F Eleveld et al.   NATURE GENETICS

ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma

(2014) Scott C. Bresler et al.   CANCER CELL

AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs

(2014) C. Wilson et al.   CANCER RESEARCH

Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration

(2013) Floor A.M. Duijkers et al.   GENE

Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation

(2013) Gnana Prakasam Krishnamoorthy et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

(2013) Justin F. Gainor et al.   JOURNAL OF CLINICAL ONCOLOGY

LDK378: A Promising Anaplastic Lymphoma Kinase (ALK) Inhibitor

(2013) Jianyong Chen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

(2013) Keith M. Giles et al.   MOLECULAR CANCER THERAPEUTICS

Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation

(2013) Hyeong Ryul Kim et al.   Molecular Oncology

Biology of the TAM Receptors

(2013) G. Lemke   Cold Spring Harbor Perspectives in Biology

The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma

(2012) Teeara Berry et al.   CANCER CELL

ABL Regulation by AXL Promotes Cisplatin Resistance in Esophageal Cancer

(2012) J. Hong et al.   CANCER RESEARCH

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Investigation of Receptor interacting protein (RIP3)-dependent Protein Phosphorylation by Quantitative Phosphoproteomics

(2012) Xiurong Wu et al.   MOLECULAR & CELLULAR PROTEOMICS

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA repair

(2012) Xue Zhang et al.   NATURE GENETICS

Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo

(2011) Dimitris Anastassiou et al.   BMC CANCER

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

(2011) Hiroshi Sakamoto et al.   CANCER CELL

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

(2011) J. M. Heuckmann et al.   CLINICAL CANCER RESEARCH

Axl-dependent signalling: a clinical update

(2011) Vyacheslav A. Korshunov   CLINICAL SCIENCE

The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models

(2011) E Normant et al.   ONCOGENE

Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer

(2011) G Mudduluru et al.   ONCOGENE

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers

(2010) T. Sasaki et al.   CANCER RESEARCH

R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer

(2010) S. J. Holland et al.   CANCER RESEARCH

Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification

(2010) S. De Brouwer et al.   CLINICAL CANCER RESEARCH

Epithelial Mesenchymal Transition Traits in Human Breast Cancer Cell Lines Parallel the CD44hi/CD24lo/- Stem Cell Phenotype in Human Breast Cancer

(2010) Tony Blick et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer

(2010) K Vuoriluoto et al.   ONCOGENE

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes

(2010) J. H. Taube et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

(2009) C. Gjerdrum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE